Strategic Acquisition Nova Biomedical's acquisition by Advanced Instruments signals a larger global platform with expanded bioprocessing and clinical diagnostics capabilities, presenting cross-sell opportunities to customers of both entities and potential expanded service contracts.

IGlobal Expansion With a presence in over 100 countries and a growing product portfolio in blood gas, critical care, glucose analysis, and bioprocessing, there is strong potential to upsell integrated instrumentation bundles and maintenance plans to international pharmaceutical and healthcare customers.

Innovation Pipeline Ongoing reinvestment in R&D and a history of launching advanced osmometers, cell imager solutions, and process monitoring tools indicate upside for early-adopter institutions seeking cutting-edge analytics and real-time data capabilities.

Private Leadership As the largest privately held IVD company in the U.S. with a reputation for integrity and long-term commitment, there are opportunities to position premium support, training programs, and extended warranties to maintain customer loyalty and recurring revenue.

Cross-Sell Synergy Existing relationships across clinical diagnostics, bioprocessing, and veterinary diagnostics create a fertile ground for cross-sell of analyzers, reagents, and software such as ArtelWare to optimize workflows and improve lab productivity.